Abstract
MicroRNAs (miRNAs) are small, non-coding RNAs, that function as post-transcriptional regulators of gene expression. Recent studies now predict that numerous miRNA molecules regulate a large proportion of the human transcriptome, thus creating a whole new research field that utilizes their potential impact on gene expression in favor of diagnosis, prognosis and drug development. MiRNAs are generated from transcription of respective genes into primary structures that usually follow a two-step maturation process in the cell nucleus and cytoplasm. Active miRNA folds downregulate protein expression either via direct repression of targeted messenger RNA (mRNA) or mRNA cleavage. They are critical factors that control human development and organogenesis and reemerge as key-molecules that profoundly influence adult cells and tissues under stress-responsive conditions. Therefore, several miRNAs exhibit dysregulated functions in almost all aspects of human pathology such as cancer, cardiovascular diseases, metabolic disorders, genetic and neurodegenerative diseases, forming tissue-specific molecular profiles that further define salient pathologic features. The present article offers an overview on miRNAs biogenesis and functional processes, major aspects of their participation in human development and milestones regarding their contribution in human diseases. Furthermore, their utility as extracellular biomarkers and the rationale behind miRNA inhibition or miRNA delivery are being discussed.
Keywords: Biomarker, cancer, cardiovascular, disease, metabolic, microRNA, therapy.
Current Topics in Medicinal Chemistry
Title:Insights in microRNAs Biology
Volume: 13 Issue: 13
Author(s): Antonios N. Gargalionis and Efthimia K. Basdra
Affiliation:
Keywords: Biomarker, cancer, cardiovascular, disease, metabolic, microRNA, therapy.
Abstract: MicroRNAs (miRNAs) are small, non-coding RNAs, that function as post-transcriptional regulators of gene expression. Recent studies now predict that numerous miRNA molecules regulate a large proportion of the human transcriptome, thus creating a whole new research field that utilizes their potential impact on gene expression in favor of diagnosis, prognosis and drug development. MiRNAs are generated from transcription of respective genes into primary structures that usually follow a two-step maturation process in the cell nucleus and cytoplasm. Active miRNA folds downregulate protein expression either via direct repression of targeted messenger RNA (mRNA) or mRNA cleavage. They are critical factors that control human development and organogenesis and reemerge as key-molecules that profoundly influence adult cells and tissues under stress-responsive conditions. Therefore, several miRNAs exhibit dysregulated functions in almost all aspects of human pathology such as cancer, cardiovascular diseases, metabolic disorders, genetic and neurodegenerative diseases, forming tissue-specific molecular profiles that further define salient pathologic features. The present article offers an overview on miRNAs biogenesis and functional processes, major aspects of their participation in human development and milestones regarding their contribution in human diseases. Furthermore, their utility as extracellular biomarkers and the rationale behind miRNA inhibition or miRNA delivery are being discussed.
Export Options
About this article
Cite this article as:
Gargalionis N. Antonios and Basdra K. Efthimia, Insights in microRNAs Biology, Current Topics in Medicinal Chemistry 2013; 13 (13) . https://dx.doi.org/10.2174/15680266113139990098
DOI https://dx.doi.org/10.2174/15680266113139990098 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
Drug Discovery in the Age of Artificial Intelligence
In the age of artificial intelligence (AI), we have witnessed a significant boom in AI techniques for drug discovery. AI techniques are increasingly integrated and accelerating the drug discovery process. These developments have not only attracted the attention of academia and industry but also raised important questions regarding the selection ...read more
From Biodiversity to Chemical Diversity: Focus of Flavonoids
Flavonoids are the largest group of polyphenols, plant secondary metabolites arising from the essential aromatic amino acid phenylalanine (or more rarely from tyrosine) via the phenylpropanoid pathway. The flavan nucleus is the basic 15-carbon skeleton of flavonoids (C6-C3-C6), which consists of two phenyl rings (A and B) and a heterocyclic ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
An Update on Hepatic Stem Cells: Bench to Bedside
Current Pharmaceutical Biotechnology The Diagnostic and Prognostic Value of Brain Natriuretic Peptide and Aminoterminal (nt)-pro Brain Natriuretic Peptide
Current Pharmaceutical Design Role of Serum and Glucocorticoid-Inducible Kinase (SGK)-1 in Senescence: A Novel Molecular Target Against Age-Related Diseases
Current Medicinal Chemistry An Engrossing History of Azidothymidine
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Conference Report: 7th Clinical Trials on Alzheimer’s Disease Annual Conference, Philadelphia, PA, USA Nov 20-22, 2014
CNS & Neurological Disorders - Drug Targets Endothelium and Oxidative Stress: The Pandora's Box of Cerebral (and Non-Only) Small Vessel Disease?
Current Molecular Medicine Pharmacological, Immunological, and Gene Targeting of the Renin-Angiotensin System for Treatment of Cardiovascular Disease
Current Pharmaceutical Design Insights Into Nicotinic Receptor Signaling in Nicotine Addiction: Implications for Prevention and Treatment
Current Neuropharmacology Therapeutic Drugs that Behave as Mechanism-Based Inhibitors of Cytochrome P450 3A4
Current Drug Metabolism Editorial (Thematic Issue: Frontiers in Atherosclerosis, Heart Disease and Diabetes)
Cardiovascular & Hematological Disorders-Drug Targets GABAA Receptors in Normal Development and Seizures: Friends or Foes?
Current Neuropharmacology The Roles of Chromatin Remodeling Proteins in Cancer
Current Protein & Peptide Science Premature Ovarian Failure (POF) Syndrome: Towards the Molecular Clinical Analysis of its Genetic Complexity
Current Medicinal Chemistry Therapies for Neurological Disease in the Mucopolysaccharidoses
Current Gene Therapy Agonist-Trafficking and Hallucinogens
Current Medicinal Chemistry Kawasakis Disease, Acrodynia, and Mercury
Current Medicinal Chemistry Postpartum Depression in Women with the FMR1 Premutation
Current Psychiatry Reviews Plasma VEGF and IL-8 Levels in Patients with Mixed Dyslipidaemia. Effect of Rosuvastatin Monotherapy or its Combination at a Lower Dose with Omega-3 Fatty Acids: A Pilot Study
Current Vascular Pharmacology Transgenerational Inheritance in the Offspring of Pregnant Women with Metabolic Syndrome
Current Pharmaceutical Biotechnology Purinergic Signalling: What is Missing and Needed Next? The Use of Transgenic Mice, Crystallographic Analysis and MicroRNA
CNS & Neurological Disorders - Drug Targets